The FDA has approved eplontersen (Wainua) for treating polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis, making it the only medication approved for self-administration via auto-injector pen for this condition.
Study shows eplontersen maintains a consistent and sustained treatment effect and reinforces its potential treating hereditary transthyretin-mediated amyloid polyneuropathy, which can lead to heart failure.
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints. | March 27, 2023
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints. | March 27, 2023
LONDON (dpa-AFX) - Ionis Pharmaceuticals Inc. (IONS) presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen